CRDF (Cardiff Oncology) Research & Development: $31.62 Mil (TTM As of Mar. 2026)


CRDF Cardiff Oncology Inc CRDF
53 GF Score
Price $1.21
GF Value $1.49
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Research & Development?

Cardiff Oncology CRDF -3.97% 53 Research & Development is $31.62 Mil as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 53/100 and a GF Value™ of $1.49 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cardiff Oncology's Research & Development for the three months ended in Mar. 2026 was $6.77 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $31.62 Mil.

Cardiff Oncology  (NAS:CRDF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cardiff Oncology Research & Development Related Terms

Cardiff Oncology Research & Development Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Research & Development Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.38 27.11 32.86 36.85 35.33

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.48 11.58 8.20 5.08 6.77
CRDF
53GF Score
Cardiff Oncology Inc CRDF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $31.62 Mil mean?
Cardiff Oncology (CRDF) has a Research & Development of $31.62 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Research & Development too high?
Cardiff Oncology's current Research & Development is $31.62 Mil. Overall, Cardiff Oncology has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Research & Development compare to VTVT and GUTS?
Cardiff Oncology's Research & Development of $31.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Research & Development is $31.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.49, compared to a current price of $1.21 — trading 18.8% below its estimated fair value. The current Research & Development is $31.62 Mil. Cardiff Oncology's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Research & Development is $31.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.21 is trading 18.8% below its estimated GF Value™ of $1.49. GuruFocus considers Cardiff Oncology to be Modestly Undervalued.

Key valuation signals for CRDF:

  • Research & Development: $31.62 Mil
  • GF Value™: $1.49 vs. price of $1.21 (18.8% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
53GF Score

Get the complete analysis for CRDF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.21
Price
$1.49
GF Value